Trial · NCT03653507
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507, Phase 3, Active not recruiting, Astellas Pharma Global Development, Inc.; results first posted 2025-01-27
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). Trials, record NCT03653507. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03653507
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
- NCT number
- NCT03653507
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 507 participants, actual
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- zolbetuximab, oxaliplatin, capecitabine, placebo
- First posted
- 2018-08-31
- Last updated
- 2026-09-28
- Other registries' IDs
- eudract:2018-000519-26
- Results first posted
- 2025-01-27
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | From the date of randomization until 61 months and 12 days | PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used. |
| Secondary | Overall Survival (OS) | From the date of randomization until 61 months and 12 days | OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used. |
| Secondary | Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | From the date of randomization until 61 months and 12 days | TTCD: time from randomization to first clinically meaning full deterioration (CMFD) that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's change from baseline (CFB) exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used. |
| Secondary | Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale | From the date of randomization until 61 months and 12 days | TTCD:time from randomization to first CMFD confirmed at next scheduled visit.OG25 evaluated gastric \& gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain, discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was "yes or no" for STO22.Linear transformation was used; score ranged from 0 to 100; higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25. CMFD: if participant's CFB exceeded pre-specified threshold (per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used |
| Secondary | Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | From the date of randomization until 61 months and 12 days | TTCD: time from randomization to first CMFD that was confirmed at the next scheduled visit.The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 (very poor) to 7 (excellent). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's CFB exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used. |
| Secondary | Objective Response Rate (ORR) | From the date of randomization until 61 months and 12 days | ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings. |
| Secondary | Duration Of Response (DOR) | From first response (CR/PR) until 61 months and 12 days | DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used. |
| Secondary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From first dose until 61 months and 12 days | An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose. |
| Secondary | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline, cycle (C) 1 day (D)1 through C60 D1 | ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead. |
| Secondary | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up | The EORTC-QLQ-C30 is a cancer-specific instrument consisting of 5 functional domain scales: physical, role, emotional, social and cognitive.It is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression Free Survival (PFS) | From the date of randomization until 61 months and 12 days | FAS | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) | From the date of randomization until 61 months and 12 days | FAS | Months | MEDIAN |
| SECONDARY | Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | From the date of randomization until 61 months and 12 days | FAS | Months | MEDIAN |
| SECONDARY | Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale | From the date of randomization until 61 months and 12 days | FAS | Months | MEDIAN |
| SECONDARY | Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | From the date of randomization until 61 months and 12 days | FAS | Months | MEDIAN |
| SECONDARY | Objective Response Rate (ORR) | From the date of randomization until 61 months and 12 days | FAS | Percentage of Participants | NUMBER |
| SECONDARY | Duration Of Response (DOR) | From first response (CR/PR) until 61 months and 12 days | FAS- All Objective Responders | Months | MEDIAN |
| SECONDARY | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From first dose until 61 months and 12 days | FAS | Participants | NUMBER |
| SECONDARY | Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline, cycle (C) 1 day (D)1 through C60 D1 | FAS | Participants | NUMBER |
| SECONDARY | Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire | Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up | FAS with available data was analyzed. | Unit on a scale | MEAN |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 outcomesResults by group3,443
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | CAPOX+ Zolbetuximab | 8.21 | 95% Confidence Interval 7.26 to 8.84 | Months | |
| Progression Free Survival (PFS) | CAPOX+ Placebo | 6.80 | 95% Confidence Interval 6.14 to 8.08 | Months | |
| Overall Survival (OS) | CAPOX+ Zolbetuximab | 14.32 | 95% Confidence Interval 12.09 to 16.39 | Months | |
| Overall Survival (OS) | CAPOX+ Placebo | 12.16 | 95% Confidence Interval 10.28 to 13.67 | Months | |
Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | CAPOX+ Zolbetuximab | 7.95 | 95% Confidence Interval 5.88 to 19.78 | Months | |
Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | CAPOX+ Placebo | 7.92 | 95% Confidence Interval 6.47 to 11.30 | Months | |
| Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale | CAPOX+ Zolbetuximab | NA | 95% Confidence Interval 28.16 to NA | Months | |
| Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale | CAPOX+ Placebo | 25.82 | 95% Confidence Interval 18.46 to NA | Months | |
| Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | CAPOX+ Zolbetuximab | 9.40 | 95% Confidence Interval 7.36 to 24.80 | Months | |
| Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | CAPOX+ Placebo | 7.49 | 95% Confidence Interval 6.11 to 9.86 | Months |
1 to 10 of 3,443Source ClinicalTrials.gov
See all 3,443 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | CAPOX+ Zolbetuximab | 254 | |
| Overall Study | STARTED | CAPOX+ Placebo | 249 | |
| Overall Study | COMPLETED | CAPOX+ Zolbetuximab | 9 | |
| Overall Study | COMPLETED | CAPOX+ Placebo | 2 | |
| Overall Study | NOT COMPLETED | CAPOX+ Zolbetuximab | 245 | |
| Overall Study | NOT COMPLETED | CAPOX+ Placebo | 247 |
Source ClinicalTrials.gov
Adverse events936
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Zolbetuximab | 90 | 254 | 255 |
| other | Anaemia | Blood and lymphatic system disorders | Capecitabine | 179 | 503 | 480 |
| other | Anaemia | Blood and lymphatic system disorders | Oxaliplatin | 179 | 503 | 480 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo | 89 | 249 | 225 |
| other | Leukopenia | Blood and lymphatic system disorders | Zolbetuximab | 17 | 254 | 41 |
| other | Leukopenia | Blood and lymphatic system disorders | Capecitabine | 25 | 503 | 63 |
| other | Leukopenia | Blood and lymphatic system disorders | Oxaliplatin | 25 | 503 | 63 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo | 8 | 249 | 22 |
| other | Neutropenia | Blood and lymphatic system disorders | Zolbetuximab | 48 | 254 | 131 |
| other | Neutropenia | Blood and lymphatic system disorders | Capecitabine | 82 | 503 | 212 |
1 to 10 of 936Source ClinicalTrials.gov
See all 936 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Zolbetuximab | 180 | 254 |
| Total, all-cause mortality | Capecitabine | 387 | 503 |
| Total, all-cause mortality | Oxaliplatin | 387 | 503 |
| Total, all-cause mortality | Placebo | 207 | 249 |
| Total, other adverse events | Zolbetuximab | 249 | 254 |
| Total, other adverse events | Capecitabine | 481 | 503 |
| Total, other adverse events | Oxaliplatin | 481 | 503 |
| Total, other adverse events | Placebo | 232 | 249 |
| Total, serious adverse events | Zolbetuximab | 123 | 254 |
| Total, serious adverse events | Capecitabine | 249 | 503 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| CAPOX+ Zolbetuximab vs CAPOX+ Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs) |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03653507
GET https://conductscience.org/api/trials/v1/NCT03653507/results?page=2